Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesAmortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Verastem (VSTM) EBITDA (2018 - 2025)

Historic EBITDA for Verastem (VSTM) over the last 8 years, with Q3 2025 value amounting to -$95.8 million.

  • Verastem's EBITDA fell 29960.36% to -$95.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$230.4 million, marking a year-over-year decrease of 16770.44%. This contributed to the annual value of -$130.6 million for FY2024, which is 4956.38% down from last year.
  • Latest data reveals that Verastem reported EBITDA of -$95.8 million as of Q3 2025, which was down 29960.36% from -$24.6 million recorded in Q2 2025.
  • Verastem's EBITDA's 5-year high stood at -$8.3 million during Q2 2024, with a 5-year trough of -$95.8 million in Q3 2025.
  • Moreover, its 5-year median value for EBITDA was -$21.0 million (2022), whereas its average is -$27.9 million.
  • Its EBITDA has fluctuated over the past 5 years, first soared by 6602.16% in 2024, then plummeted by 29960.36% in 2025.
  • Over the past 5 years, Verastem's EBITDA (Quarter) stood at -$16.5 million in 2021, then dropped by 1.79% to -$16.8 million in 2022, then fell by 19.01% to -$20.0 million in 2023, then tumbled by 223.47% to -$64.6 million in 2024, then tumbled by 48.37% to -$95.8 million in 2025.
  • Its last three reported values are -$95.8 million in Q3 2025, -$24.6 million for Q2 2025, and -$45.5 million during Q1 2025.